| Hemophilia A
Xyntha vs Afstyla
Side-by-side clinical, coverage, and cost comparison for hemophilia a.Deep comparison between: Xyntha vs Afstyla with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAfstyla has a higher rate of injection site reactions vs Xyntha based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Afstyla but not Xyntha, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Xyntha
Afstyla
At A Glance
IV infusion
3 times weekly (prophylaxis)
Factor VIII replacement
IV infusion
2-3 times weekly
Recombinant Factor VIII
Indications
- Hemophilia A
- Hemophilia A
Dosing
Hemophilia A - On-demand / Bleeding episodes Dose calculated as body weight (kg) x desired FVIII rise (IU/dL) x 0.5; minor bleeds: 20-40 IU/dL target every 12-24 hrs; moderate: 30-60 IU/dL every 12-24 hrs; major: 60-100 IU/dL every 8-24 hrs; IV infusion.
Hemophilia A - Perioperative management Minor surgery: 30-60 IU/dL target every 12-24 hrs for 3-4 days; major surgery: 60-100 IU/dL target every 8-24 hrs until adequate local hemostasis achieved; IV infusion.
Hemophilia A - Routine prophylaxis Adults and adolescents (>=12 years): 30 IU/kg 3 times weekly IV; adjust dose or frequency based on clinical response.
Hemophilia A - On-demand treatment and control of bleeding Target Factor VIII activity 20-40 IU/dL for minor bleeds, 30-60 IU/dL for moderate bleeds, and 60-100 IU/dL for major/life-threatening bleeds; repeat IV injection every 8-24 hours until bleeding is resolved. Dose (IU) = body weight (kg) x desired Factor VIII rise (IU/dL) x 0.5.
Hemophilia A - Routine prophylaxis Adults and adolescents (>=12 years): 20-50 IU/kg IV 2-3 times weekly; children may require more frequent dosing based on pharmacokinetic data and individual response.
Hemophilia A - Perioperative management Target 30-60 IU/dL for minor surgery (repeat every 24 hours for >=1 day); target 80-100 IU/dL for major surgery (repeat every 8-24 hours until adequate wound healing, then maintain 30-60 IU/dL for >=7 more days) via IV injection.
Contraindications
- Life-threatening immediate hypersensitivity reactions, including anaphylaxis, to XYNTHA or its components, including hamster proteins
- Life-threatening hypersensitivity reactions, including anaphylaxis, to AFSTYLA or any excipient (e.g., polysorbate 80) or to hamster proteins
Adverse Reactions
Most common (>=10%) Headache, arthralgia, pyrexia, cough
Postmarketing Inadequate therapeutic response
Most common (>0.5%) Factor VIII inhibition (in previously untreated patients), hypersensitivity, dizziness
Postmarketing Factor VIII inhibitor development
Pharmacology
XYNTHA temporarily replaces missing clotting factor VIII needed for effective hemostasis; treatment normalizes activated partial thromboplastin time (aPTT) over the effective dosing period.
AFSTYLA is a recombinant single-chain Factor VIII with a truncated B-domain and covalent linkage between heavy and light chains that replaces missing Coagulation Factor VIII needed for effective hemostasis; it exhibits higher VWF affinity relative to full-length rFVIII, providing increased molecular stability and protection from degradation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Xyntha
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Afstyla
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Xyntha
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (0/8)
Afstyla
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Xyntha
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Afstyla
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Inherited and Acquired Factor Deficiencies - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Inherited and Acquired Factor Deficiencies - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
XynthaView full Xyntha profile
AfstylaView full Afstyla profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.